Gri Bio Inc (GRI)

$2.52 +0.01 (0.40%)
Market Cap 3.63M
Revenue (ttm) 0.00
Net Income (ttm) -11.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 72,200
Avg Vol 100,436
Day's Range N/A - N/A
Shares Out 1.45M
Stochastic %K 62%
Beta -1.34
Analysts Sell
Price Target $25.00

Company Profile

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a no...

Industry: Biotechnology
Sector: Healthcare
Phone: 619 400 1170
Address:
2223 Avenida de la Playa, Suite 208, La Jolla, United States
HeartMe
HeartMe Apr. 20 at 9:07 PM
$GRI $CISS $UONE $SLE case
0 · Reply
TruthTooPower
TruthTooPower Apr. 16 at 6:31 PM
$GRI!!! 🤓🤓🤓🤓🤓🙌🙌🙌🙌🙌 Ka1954 we got iit!!!
0 · Reply
LuckyRing
LuckyRing Apr. 13 at 3:09 PM
$GRI CEO has screwed the shareholders
0 · Reply
ka1954
ka1954 Apr. 13 at 3:06 PM
$GRI this stock is fucked up. went to 2.77 and now 2.20. what a joke
0 · Reply
LiveCommander
LiveCommander Apr. 10 at 6:27 PM
$GRI waking up 🤨 Recent 1-for-28 RS → float reset ~1.4M float 👉 still extremely thin No major catalyst → this is structure + momentum… Low float like this… volume hits → it moves fast! Watching closely 👀
0 · Reply
topstockalerts
topstockalerts Apr. 10 at 4:53 PM
$GRI not sure where this stops if buyers keep showing up like this
2 · Reply
SPARTANVI
SPARTANVI Apr. 10 at 4:52 PM
$GRI wants 3$+ here nice Uptrend $FUSE watching $UCAR crazy run
0 · Reply
anonAlb
anonAlb Apr. 10 at 4:49 PM
$GRI time to break 🔥🔥🔥🔥🔥🔥🔥😎🫡
0 · Reply
SPARTANVI
SPARTANVI Apr. 10 at 4:47 PM
$GRI 👀
0 · Reply
ka1954
ka1954 Apr. 10 at 4:41 PM
$GRI i want to see 200% to fucking kill the shorts
0 · Reply
Latest News on GRI
GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

Apr 8, 2026, 8:30 AM EDT - 13 days ago

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

Feb 17, 2026, 9:15 AM EST - 2 months ago

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

Feb 5, 2026, 9:15 AM EST - 2 months ago

GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

Feb 4, 2026, 8:45 AM EST - 2 months ago

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF

Jan 28, 2026, 8:45 AM EST - 2 months ago

GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF

GRI Bio Announces Reverse Stock Split

Jan 21, 2026, 4:01 PM EST - 3 months ago

GRI Bio Announces Reverse Stock Split

GRI Bio Announces Closing of $8.0 Million Public Offering

Dec 12, 2025, 4:05 PM EST - 4 months ago

GRI Bio Announces Closing of $8.0 Million Public Offering

GRI Bio Announces Pricing of $8,000,000 Million Public Offering

Dec 11, 2025, 9:15 AM EST - 4 months ago

GRI Bio Announces Pricing of $8,000,000 Million Public Offering

GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Dec 10, 2025, 4:05 PM EST - 4 months ago

GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Sep 11, 2025, 8:45 AM EDT - 7 months ago

GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 14, 2025, 9:15 AM EDT - 8 months ago

GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment

Jul 31, 2025, 1:50 PM EDT - 9 months ago

GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment

GRI Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 9 months ago

GRI Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Jul 1, 2025, 8:45 AM EDT - 10 months ago

GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Jun 26, 2025, 8:00 AM EDT - 10 months ago

GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio to Participate in the Virtual Investor Closing Bell Series

May 21, 2025, 9:15 AM EDT - 11 months ago

GRI Bio to Participate in the Virtual Investor Closing Bell Series

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

May 16, 2025, 9:15 AM EDT - 1 year ago

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

May 15, 2025, 8:35 AM EDT - 1 year ago

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

May 8, 2025, 8:45 AM EDT - 1 year ago

GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

May 7, 2025, 9:15 AM EDT - 1 year ago

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

Apr 16, 2025, 8:35 AM EDT - 1 year ago

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

GRI Bio Announces Closing of $5.0 Million Public Offering

Apr 2, 2025, 4:05 PM EDT - 1 year ago

GRI Bio Announces Closing of $5.0 Million Public Offering

GRI Bio Announces Pricing of $5.0 Million Public Offering

Apr 1, 2025, 11:15 AM EDT - 1 year ago

GRI Bio Announces Pricing of $5.0 Million Public Offering

Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?

Apr 1, 2025, 11:07 AM EDT - 1 year ago

Why Is Nano Cap GRI Bio Stock Skyrocketing On Tuesday?

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

Mar 31, 2025, 8:00 AM EDT - 1 year ago

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

GRI Bio Participates in a Virtual Investor CEO Connect Segment

Mar 18, 2025, 9:05 AM EDT - 1 year ago

GRI Bio Participates in a Virtual Investor CEO Connect Segment

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

Mar 17, 2025, 8:05 AM EDT - 1 year ago

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule

Mar 11, 2025, 8:35 AM EDT - 1 year ago

GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule

GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 9:00 AM EST - 1 year ago

GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

Dec 23, 2024, 9:00 AM EST - 1 year ago

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

Nov 21, 2024, 8:45 AM EST - 1 year ago

GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

Nov 14, 2024, 4:20 PM EST - 1 year ago

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

Oct 24, 2024, 8:30 AM EDT - 1 year ago

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

GRI Bio Announces Exercise of Warrants

Oct 21, 2024, 5:35 PM EDT - 1 year ago

GRI Bio Announces Exercise of Warrants

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

Oct 16, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

Sep 30, 2024, 8:30 AM EDT - 1 year ago

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

Sep 25, 2024, 8:45 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 8:45 AM EDT - 1 year ago

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GRI Bio to Present at the 2024 European Respiratory Congress

Sep 4, 2024, 8:45 AM EDT - 1 year ago

GRI Bio to Present at the 2024 European Respiratory Congress

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 14, 2024, 8:05 AM EDT - 1 year ago

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

Jul 15, 2024, 9:05 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

Jul 11, 2024, 9:20 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

GRI Bio Regains Compliance with Nasdaq

Jul 8, 2024, 9:05 AM EDT - 1 year ago

GRI Bio Regains Compliance with Nasdaq

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

Jul 2, 2024, 9:05 AM EDT - 1 year ago

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

GRI Bio to Present at the 8th Annual IPF Summit

Jul 1, 2024, 8:45 AM EDT - 1 year ago

GRI Bio to Present at the 8th Annual IPF Summit

GRI Bio Announces Closing of $4.0 Million Public Offering

Jun 28, 2024, 4:05 PM EDT - 1 year ago

GRI Bio Announces Closing of $4.0 Million Public Offering

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

Jun 27, 2024, 9:00 AM EDT - 1 year ago

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs

May 22, 2024, 9:15 AM EDT - 2 years ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

May 21, 2024, 8:35 AM EDT - 2 years ago

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

May 20, 2024, 8:45 AM EDT - 2 years ago

GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

HeartMe
HeartMe Apr. 20 at 9:07 PM
$GRI $CISS $UONE $SLE case
0 · Reply
TruthTooPower
TruthTooPower Apr. 16 at 6:31 PM
$GRI!!! 🤓🤓🤓🤓🤓🙌🙌🙌🙌🙌 Ka1954 we got iit!!!
0 · Reply
LuckyRing
LuckyRing Apr. 13 at 3:09 PM
$GRI CEO has screwed the shareholders
0 · Reply
ka1954
ka1954 Apr. 13 at 3:06 PM
$GRI this stock is fucked up. went to 2.77 and now 2.20. what a joke
0 · Reply
LiveCommander
LiveCommander Apr. 10 at 6:27 PM
$GRI waking up 🤨 Recent 1-for-28 RS → float reset ~1.4M float 👉 still extremely thin No major catalyst → this is structure + momentum… Low float like this… volume hits → it moves fast! Watching closely 👀
0 · Reply
topstockalerts
topstockalerts Apr. 10 at 4:53 PM
$GRI not sure where this stops if buyers keep showing up like this
2 · Reply
SPARTANVI
SPARTANVI Apr. 10 at 4:52 PM
$GRI wants 3$+ here nice Uptrend $FUSE watching $UCAR crazy run
0 · Reply
anonAlb
anonAlb Apr. 10 at 4:49 PM
$GRI time to break 🔥🔥🔥🔥🔥🔥🔥😎🫡
0 · Reply
SPARTANVI
SPARTANVI Apr. 10 at 4:47 PM
$GRI 👀
0 · Reply
ka1954
ka1954 Apr. 10 at 4:41 PM
$GRI i want to see 200% to fucking kill the shorts
0 · Reply
frankyboyz
frankyboyz Apr. 10 at 4:34 PM
who is tapping $GRI and why? hmmmm
1 · Reply
totti09
totti09 Apr. 10 at 2:59 PM
$GRI
0 · Reply
SPARTANVI
SPARTANVI Apr. 10 at 2:45 PM
$GRI above 2.80 ill join Has nice potential
0 · Reply
SPARTANVI
SPARTANVI Apr. 10 at 2:38 PM
$GRI watching nice setup
0 · Reply
LuckyRing
LuckyRing Apr. 10 at 2:13 PM
$GRI Someone needs to post on their X page: CEO makes $750,000 a year while the company keeps on tanking! Stock is down 100%. What a scam! GRI Bio blocked me on X. Truth hurts
0 · Reply
ThotBroker
ThotBroker Apr. 9 at 4:57 PM
$GRI ❤️‍🔥
0 · Reply
Bgirl_smirk
Bgirl_smirk Apr. 9 at 7:21 AM
$GRI $UCAR $KUST $BAOS watching today for daytrade
1 · Reply
SPARTANVI
SPARTANVI Apr. 9 at 4:27 AM
$GRI Watching this one aswell, Bio tickers been hot Above 2.80 this could see a nice move
0 · Reply
Sanjaynaik2011
Sanjaynaik2011 Apr. 8 at 8:39 PM
$GRI UAE IS GETTING THEIR ASS WHOOP BY IRAN!!! I WONDER IF THEY CAN EVEN SURVIVE FOR NEXT FEW MONTHS!!!
0 · Reply
Sanjaynaik2011
Sanjaynaik2011 Apr. 8 at 8:37 PM
$GRI Looks like a crash has begun. Will this drop to $1.50-$1.80? Some paid so called analyst claims that this will reach $40... What a JOKE!!! 😂😂🤣😂🤣😂
0 · Reply
mombyry
mombyry Apr. 8 at 8:12 PM
$GRI This company does the same game every 2 weeks. Go up by insider and then put it 50 cents down and you got traped controlling the price the entire day. Price is going to stay there up to close. They make mone like this. No sales, no income. garbage!
0 · Reply
focafoca99
focafoca99 Apr. 8 at 8:04 PM
$GRI received a UAE patent allowance covering its type 2 diverse NKT cell agonists for inflammatory conditions.
0 · Reply